YD Bio is a Cayman Islands-incorporated, early-stage biotech headquartered in Taipei, Taiwan, operating across three businesses: cancer diagnostics, clinical trial supply chain services, and eye health products. The company's current revenue comes almost entirely from its clinical trial supply chain subsidiary, Yong Ding, which procures and delivers clinical trial drugs, medical devices, and lab equipment to pharma companies running trials in Taiwan. Novartis and Alcon together account for over half of total revenue. YD Bio's strategic focus is on its OkaiDx cancer diagnostics platform — two blood tests for pancreatic and breast cancer detection that use cfDNA methylation analysis to identify abnormal DNA patterns in a blood sample. These tests are offered as laboratory-developed tests (LDTs) through a CLIA- and CAP-accredited lab in Washington State, marketed to healthcare providers via the EG Telehealth Platform. The underlying technology is licensed from EG BioMed, a closely affiliated Taiwan biotech, and the tests have not received FDA approval. YD Bio also sells FDA-cleared contact lenses and an OTC artificial tear product in the U.S., and is developing exosome-based eye drop and injectable treatments for dry eye and retinal disorders, though these remain in early preclinical stages. YD Bio does not own any patents — all key technology is licensed from affiliated entities. The company is pursuing a merger with EG BioMed and a roughly $26M acquisition of cell sciences company SSMC to expand its capabilities.